Morning Eyecatchers: BT Group second-quarter sales £5.07 billion

* BT Group second-quarter sales £5.07 billion; ebitda £1.31 billion; net income £428 million; eps 5.4p; sees 3-4% sales decline in full year; sees full-year capital expenditure to reduce to around £2.68 billion; sees improvement in global services * 3i Group net asset value 286p; cautious about the economy, but confident in the strength of portfolio

* Amec sees trading in line withe expectations; sees ebita margins approaching 8% expected in full-year 2009

* Dairy Crest first-half sales £803.7 million, pre-tax profit £34 million; to focus on cash management in second-half; interim dividend 5.3p

* WH Smith 10-week group sales down 1%; like-for-like sales down 2%; high street like-for-like sales down 4%; cautious re consumer environment; has 'planned accordingly' for shopping period

* Stobart has secured a major three-year distribution contract with Unilever UK which will create £60 million of extra business

* Aga outlook brighter this autumn; has seen seasonal upturn in activity; will beat cash target

* Aveva net £15.6 million; remains cautious on the outlook for 2010

* BBA Aviation performance for period July 1 to November 11 in line; signs of stabilisation in most of markets have continued; rate year-on-year decline in flight activity moderated to 22% to end of October; year-on-year reduction in commercial aviation and flight activity unchanged from half-year at 10%

* Henry Boot performance remained in line with forecasts; in compliance with all its banking covenants; valuation in property beginning to stabilise

* Centrica performing in line with expectations; lower gas output offset by lower tax rate; on track to exceed £100 million target for cost savings

* Eurasian natural Resources full-year capex to total $1.2 billion; sustainability of China recovery more convincing; industry outlook for 2010 uncertain; forecast modest contribution from CAMEC in 20910

* Galiform continued to perform resiliently and has seen satisfactory performance on all key measures since June; trading conditions have remained stable with signs of an improvement in market sentiment emerging; trading in first 44 weeks 2009 down 4.6%

* Hikma Pharma seeing an acceleration of sales in fourth quarter; expect to deliver full-year sales growth of approximately 10%; confident group will deliver full-year gross margin of around 46%, up from 44% in 2008

* Keller Group most markets remain challenging; margins since first-half still below 2008; expectations for full-year remain unchanged

* Safestore revenue for fourth quarter 3% up on fourth-quarter 2008; continues to see increasing level of enquiries

* Serco Group YTD contract awards reach £4.5 billion; wins £1 billion of contracts in second half; positive on prospects for future; financial position remains strong

* SIG trading environment still testing; sees early signs of slow rate of decline; sales broadly in line with management targets; confident to operate with banking covenants

* Skyepharma trading in line with expectations

* Synergy Health first-half revenues up 7.2% to £142.7 million; pre-tax profit up 19.8% to £14.9 million; starting to generate returns on capital investment recently made in Asia and Europe; interim dividend up 16.7%

* Trinity Mirror full-year results to be in line with expectations; conditions have remained difficult; closed four regional titles since fist-half; decline in revenues improving